| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | 0.0084 | 0.8 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | Roscovitine | GDSC1000 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.008 | 0.8 |
| mRNA | UNC0321 | CTRPv2 | pan-cancer | AAC | 0.0087 | 0.8 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.8 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.0087 | 0.8 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.0081 | 0.8 |